Skip to content

Robotic Nipple Sparing Mastectomy with Immediate Reconstruction

Robotic Nipple Sparing Mastectomy with Immediate Reconstruction with Prepectoral Implant: a Single Center, Prospective Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06860217
Enrollment
24
Registered
2025-03-05
Start date
2025-04-30
Completion date
2032-04-30
Last updated
2025-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRCA Mutation, Breast Cancer, DCIS

Keywords

Robotic Mastectomy, Nipple-sparing mastectomy, Breast reconstruction

Brief summary

Aim of this trial is to verify whether the patients' quality of life can be improved by a less invasive surgical procedure and whether the use of robotic technique for nipple-sparing mastectomy associated to prepectoral direct implant procedure can impact on perioperative and postoperative period and on oncologic outcome.

Detailed description

Muscle coverage, whether total or partial, has been historically advocated as the preferred approach after nipple sparing mastectomy because it adds an additional layer of vascularized coverage to the implant. However, current practices have evolved toward prepectoral implant reconstruction as it reduces animation deformity, pain, and muscle spasms, compared with the subpectoral approach, while maintaining optimal esthetic results. One of the limitations to the use of the prepectoral (subcutaneous) implant in ordinary surgery (open technique) is related to the fact that the implant is in direct contact with the surgical wound, giving reasons of high rate of implant loss due to wound dehiscence. In this sense, the extra-mammary localization of the surgical wound (as during robotic mastectomy) allows the positioning of the prepectoral implant in greater safety. Robotic nipple-sparing mastectomy with immediate breast prepectoral implant reconstruction may allow for more precise anatomic dissection and improved cosmetic outcomes over conventional open nipple-sparing mastectomy with retro-pectoral implant reconstruction; however, data about the feasibility, safety of the prepectoral reconstruction is limited as well as Quality of Life (QoL) evaluation. The aim of this single center, prospective trial is to analyze the perioperative data, postoperative complications, oncologic outcomes as well as to analyze the patient reported outcome measures (PROMs) of 24 consecutive patients undergoing robotic nipple-sparing mastectomy and reconstruction with prepectoral implant. Concomitant endpoint is to compare operative features outcome measures and post-operative outcome complications. A second-phase time line is to evaluate the long-term analysis of cumulative incidence of loco-regional recurrence, distant recurrences, the disease free survival and the overall survival with a median follow up of 5 years.

Interventions

OTHERRobotic Nipple-Sparing Mastectomy

Patient will undergo to nipple sparing mastectomy and breast reconstruction, conducted using robot

Sponsors

European Institute of Oncology
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Single center prospective trial

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Candidates to nipple-sparing mastectomy and immediate breast reconstruction for invasive breast cancer, ductal carcinoma in situ (DCIS), BReast CAncer gene (BRCA) mutation carriers * Any age * Negative preoperative assessment of nipple-areola complex * Absence of skin involvement * Low probability to have positivity of nipple-areola complex tissue intra-operative frozen section * Breast volume ≤ Bra IV * No hard smoking (defined as \<=20 cigarettes/day) * Low and intermediate risk for anesthesia (American Society of Anesthesiologists (ASA) Scale) * Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. * Patients must be accessible for follow-up

Exclusion criteria

* Previous thoracic radiation therapy for any reason * Inflammatory Breast Cancer * Pregnancy * Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study. * Uncompensated Diabetes Mellitus

Design outcomes

Primary

MeasureTime frameDescription
Patient satisfaction reagarding nipple areola complex5 yearsCompletion of Nipple Areola Complex (NAC) questionnaire (minimum value: 1, maximum value: 5 - higher scores mean a greater agreement with the statement)
Post operative complications1 monthNumber of post operative complications (pain, skin or nipple-areola injury or necrosis or infection, hematoma, seroma)
Post operative pain1 monthEvaluation of postoperative pain by White and Song scale (minimum value: 0, maximum value: 2 - lower scores indicate higher pain)
Length of stay of patients1 monthEvaluation of average length of stay of patients
Patient quality of life after surgery5 yearsCompletion of BREAST-Q questionnaire (higher answers to each item reflect a better outcome)
Patient satisfaction regarding body image5 yearsCompletion of Hopwood's body image scale (BIS) questionnaire (minimum value: 0, maximum value: 3 - higher scores indicate lower satisfaction)
Surgery time1 monthEvaluation of average length of robotic procedure

Secondary

MeasureTime frameDescription
Cumulative incidence of axillary recurrences5 yearsNumber of axillary recurrences
Cumulative incidence of distant recurrences5 yearsNumber of distant recurrences
Disease-free survival (DFS)5 yearsInterval from surgery to recurrence of disease
Overall survival (OS)5 yearsInterval from surgery to death or last known alive date
Cumulative incidence of local recurrence5 yearsNumber of local recurrence

Countries

Italy

Contacts

Primary ContactPaolo Veronesi, MD
paolo.veronesi@ieo.it+39 0294371091
Backup ContactMara Negri
mara.negri@ieo.it+39 0257489536

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026